We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Drug Company Buyout to Boost Development of Liver Disease Drugs

By LabMedica International staff writers
Posted on 20 Apr 2016
A strategic buyout will broaden the role of an American pharmaceutical research and manufacturing company in the area of liver diseases.
 
 
 
The biopharmaceutical company Gilead Sciences (Foster City, CA, USA) has announced the purchase of Nimbus Apollo Inc., a subsidiary of Nimbus Therapeutics LLC (Cambridge, MA, USA). More...
Gilead is set to pay 400 million USD for Nimbus Apollo, and the parent company could receive up to another 800 million USD, if Nimbus Apollo's drug development program meets certain milestones in testing results and medicine approval and sales.
 
 
 
Implementation of the agreement will give Gilead access to the experimental drug NDI-010976, which is being tested for the treatment of non-alcoholic steatohepatitis, known by the acronym NASH. This disorder causes inflammation, cell damage, progressive scarring, and cirrhosis of the liver. An estimated 15 million Americans suffer from NASH.
 
 
 
In February 2016, the drug NDI-010976 was awarded [US] Food and Drug Administration "fast-track" designation, which speeds up regulatory review and approval. The drug blocks two forms of the enzyme acetyl CoA carboxylase (ACC), which is involved in cellular fatty acid metabolism.
 
 
 
Dr. Norbert Bischofberger, CSO at Gilead, said, "The acquisition will complement and further strengthen Gilead's ongoing efforts to address unmet needs in NASH."
 
 
 
In addition to the acquisition of NDI-010976, the purchase brings to Gilead Nimbus' breakthrough computational chemistry platform that was designed to enable rapid discovery, design, and tweaking of potential medicinal compounds.
 
 
Related Links: 
 
 


 

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.